New, Effective Low Dose Estrogen Therapy Introduced to National Media
20 Juin 2007 - 5:30PM
PR Newswire (US)
Elestrin(TM) Represents An Effective Low Dose Treatment Option to
Treat Hot Flashes NEW YORK, June 20 /PRNewswire-FirstCall/ --
Bradley Pharmaceuticals, Inc. (NYSE:BDY) today introduced
Elestrin(TM) (estradiol gel 0.06%) to the national media.
Elestrin(TM) is an effective, low dose transdermal estrogen therapy
approved by the Food and Drug Administration (FDA) in December 2006
for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause. Elestrin(TM) was launched last week by
the Company's Kenwood Therapeutics division and is now available by
prescription at pharmacies nationwide. An editors' launch meeting
was held today in New York City led by Marie Lugano, founder of the
American Menopause Foundation. Dr. Michelle Warren of Columbia
University, a key opinion leader on menopause, provided an overview
of the menopause marketplace. Dr. Michael Snabes, an expert in the
field of reproductive endocrinology, provided information on
clinical studies about Elestrin(TM). "Every woman is unique, and so
is the way she experiences menopause," said Ms. Lugano. "It is
critical, therefore, that women research the issues, understand the
various treatment options available, and discuss them with their
doctor. Armed with the right information, women can better manage
their menopause symptoms effectively." "Menopause therapy is
shifting toward low-dose regimens, and Elestrin(TM) offers women a
new, effective low dose treatment option," said Daniel Glassman,
President and CEO of Bradley Pharmaceuticals. "Elestrin(TM)
addresses the guidelines set forth by the FDA, American College of
Obstetricians and Gynecologists (ACOG), North American Menopause
Society (NAMS), and the New England Journal of Medicine that
hormone therapy should be used at a low effective dose for the
shortest duration of time." In addition to being an effective low
dose estrogen therapy, Elestrin(TM) dries quickly within five
minutes and is applied once-daily over a small area of the upper
arm and/or shoulder. Dr. Michael Snabes, co-author of "Low Dose of
Transdermal Estradiol Gel for the Treatment of Symptomatic
Postmenopausal Women," which was published in the March 2007
edition of Journal of Obstetrics & Gynecology, noted that
"During the 12-week clinical trial, Elestrin(TM) was proven to
significantly reduce the frequency and severity of hot flashes.
Reductions in both the frequency and severity of hot flashes varied
depending on the dosage." "We now have the option to prescribe a
new, low effective dose of estrogen therapy to patients," said Dr.
Michelle Warren, Medical Director of The Center for Menopause,
Hormonal Disorders and Women's Health at Columbia University.
"Elestrin(TM) will provide physicians with an important treatment
option for patients who choose to manage their hot flashes."
Important Product Safety Information About Elestrin(TM): Close
clinical surveillance of all women taking estrogens is important.
Adequate diagnostic measures should be undertaken to rule out
malignancy in cases of undiagnosed persistent or recurring abnormal
vaginal bleeding. Long-term continuous administration of estrogen,
with or without progestin, has shown an increased risk of
endometrial, breast and ovarian cancers. Estrogens with or without
progestins should not be used for the prevention of cardiovascular
disease or dementia. An increased risk of developing probable
dementia in postmenopausal women 65 years of age or older was
reported with estrogen-alone use, as well as, in combination with
progestin. Estrogen-alone therapy has been associated with an
increased risk of stroke and deep vein thrombosis. Estrogen plus
progestin therapy has been associated with an increased risk of
myocardial infarction, stroke, invasive breast cancer, pulmonary
emboli and deep vein thrombosis. Estrogens should be discontinued
immediately if any of these events occur or are suspected. Estrogen
with or without progestin should be prescribed at the lowest
effective doses and for the shortest duration consistent with
treatment goals and risks for the patient. An increase in
gallbladder disease requiring surgery in postmenopausal women
receiving estrogens has been reported. Estrogen therapy may lead to
severe hypercalcemia in patients with breast cancer and bone
metastases. Retinal vascular thrombosis has been reported in
patients receiving estrogens. Estrogen products should not be used
in women with undiagnosed abnormal genital bleeding; known,
suspected or history of breast cancer; known or suspected
estrogen-dependent neoplasia; active or history of deep vein
thrombosis or pulmonary embolism; active or recent (within the past
year) arterial thromboembolic disease (e.g., stroke, myocardial
infarction); liver dysfunction or disease; known or suspected
pregnancy. The most frequently reported adverse events in clinical
trials were nasopharyngitis, breast tenderness, upper respiratory
tract infection, and metrorrhagia. For additional important
information about Elestrin(TM), please view full prescribing
information at http://www.bradpharm.com/ or request full
prescribing information by contacting Bradley Pharmaceuticals at
973-882-1505. About Bradley Pharmaceuticals, Inc. Bradley
Pharmaceuticals, Inc. was founded in 1985 as a specialty
pharmaceutical company and markets to niche physician specialties
in the U.S. and international markets. Bradley's success is based
upon its core strengths in marketing and sales, which enable the
Company to Commercialize brands that fill unmet patient and
physician needs; Develop new products through life cycle
management; and In-License phase II and phase III drugs with
long-term intellectual property protection that upon approval
leverage Bradley's marketing and sales expertise to increase
shareholder value. Bradley Pharmaceuticals is comprised of Doak
Dermatologics, specializing in therapies for dermatology and
podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN,
respiratory and other internal medicine brands; and A. Aarons,
which markets authorized generic versions of Doak and Kenwood
therapies. Safe Harbor for Forward-Looking Statements: This release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or
may occur in the future, such as Bradley's plans to in-license,
develop and launch new and enhanced products with long-term
intellectual property protection or other significant barriers to
market entry, sales and earnings estimates, other predictions of
financial performance, timing of payments on indebtedness, launches
by Bradley of new products, market acceptance of Bradley's
products, and the achievement of initiatives to enhance corporate
governance and long-term shareholder value. Forward-looking
statements are based on Bradley's experience and perception of
current conditions, trends, expected future developments and other
factors it believes are appropriate under the circumstances and are
subject to numerous risks and uncertainties, many of which are
beyond Bradley's control. These risks and uncertainties include
Bradley's ability to: Launch VEREGEN(TM) at the end of 2007;
predict the safety and efficacy of ELESTRIN(TM) and VEREGEN(TM) in
a commercial setting; estimate sales; maintain adequate inventory
levels; implement the returns and inventory optimization plan
timely, if at all; reduce product returns; comply with the
restrictive covenants under its credit facility; refinance its
credit facility; access the capital markets on attractive terms or
at all; favorably resolve the pending SEC informal inquiry;
maintain or increase sales of its products; or effectively react to
other risks and uncertainties described from time to time in
Bradley's SEC filings, such as fluctuation of quarterly financial
results, estimation of product returns, chargebacks, rebates and
allowances, concentration of customers, reliance on third party
manufacturers and suppliers, litigation or other proceedings
(including the pending class action and shareholder derivative
lawsuits), government regulation and stock price volatility.
Further, Bradley cannot accurately predict the impact on its
business of the approval, introduction, or expansion by competitors
of generic or therapeutically equivalent or comparable versions of
Bradley's products or of any other competing products. In addition,
actual results may differ materially from those projected. Bradley
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. DATASOURCE: Bradley Pharmaceuticals, Inc. CONTACT:
Elizabeth Hewitt, +1-212-829-0002, Ext. 107, , for Bradley
Pharmaceuticals, Inc.; or Cecelia Heer of Bradley Pharmaceuticals,
Inc., +1-973-882-1505, Ext. 252, Web site:
http://www.bradpharm.com/
Copyright
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024